Takeda's Actos sales suffer on safety questions; Valeant sales hike helps turn to profit;

@FiercePharma:  GSK settles U.S. investigation for $3B. News | Follow @FiercePharma

> Takeda Pharmaceutical posted weaker Q3 sales as safety questions hurt its diabetes drug Actos; the Japanese drugmaker also cut its full-year profit forecast on Nycomed buyout costs and the strong yen. News

> Valeant Pharmaceuticals posted third-quarter revenue of $601 million, a 40% increase year-over-year including recent acquisitions, and an organic growth rate of 15%. Valeant release

> Jordan's Hikma Pharmaceuticals saw increased sales of branded drugs as turmoil in its Middle Eastern markets eased. Item

> One of Taro Pharmaceutical's independent shareholders lambasted a minority-buyout offer from Sun Pharmaceutical Industries and called for a "truly independent" board committee to evaluate it. Release

> Brazil Pharma agreed to pay $260 million for the Big Ben chain of pharmacies, with 146 stores concentrated in the country's north and northeast. Story

> Aoxing Pharmaceuticals' Chinese subsidiary won government funding for improvements to its manufacturing facility in Hebei Province. Report

> Vanda Pharmaceuticals posted $8 million in revenue for the third quarter, fueled by royalties on its Fanapt antipsychotic drug, which saw a 10% increase in prescriptions year over year. Article

> Germany's Grünenthal tapped Jan-Uwe Claas to head up its U.K. subsidiary. Report

Biotech News

@FierceBiotech: Gates' legendary discipline transforms vaccine effort. Item | Follow @FierceBiotech 

@JohnCFierce: Inhibitex shares have more than doubled since their release discussing their interferon-free approach to hep C. Story | Follow @JohnCFierce

@RyanMFierce:  Looks like Pfizer won't be axing as many R&D workers at Sandwich UK site as we thought. Retaining 650 workers. News | Follow @RyanMFierce

> FDA gives new shot to Vivus obesity drug. News

And Finally... Can't sleep? Blame these neurons. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.